← back to search

Ying Cheng

Jilin Province Tumor Hospital · CN
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Lung Cancer Research Studies, Melanoma and MAPK Pathways, Cancer Mechanisms and Therapy, and Lung Cancer Treatments and Mutations.
h-index
15
citations
1,081
works
46
NIH funding
primary concept
email

Recent publications

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA
Journal of Thoracic Oncology 2025cited by 8position: middledoi
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
European Journal of Cancer 2024cited by 26position: middledoi
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory <i>EGFR</i>-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
Journal of Clinical Oncology 2024cited by 17position: middledoi
OONO–/MMP2/MMP9 pathway-mediated apoptosis of porcine granulosa cells is associated with DNA damage
Reproduction 2023cited by 11position: middledoi
Dietary folic acid supplementation improves semen quality and spermatogenesis through altering autophagy and histone methylation in the testis of aged broiler breeder roosters
Theriogenology 2021cited by 24position: middledoi
Application of neurally adjusted ventilatory assist in ventilator weaning of infants ventilator weaning
Brain and Behavior 2021cited by 10position: middledoi
A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
iScience 2020cited by 8position: middledoi
Current Development Status of MEK Inhibitors
Molecules 2017cited by 293position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Hongqi Tian · Chinese Academy of Medical Sciences & Peking Union Medical College3 papers (2017–2024)Quanwei Wei · Nanjing Agricultural University2 papers (2021–2023)Remy B. Verheijen · Johnson & Johnson (United States)1 papers (2024–2024)Alexander I. Spira · Inova Fairfax Hospital1 papers (2024–2024)James Chih‐Hsin Yang · National Institutes of Health1 papers (2024–2024)Zhiguo Luo · Shanghai Medical College of Fudan University1 papers (2024–2024) · 1 papers (2020–2020)Xiaoli He · Hunan University1 papers (2020–2020)Mahadi Baig · Johnson & Johnson (United States)1 papers (2024–2024)Yu Chen · Shenyang Pharmaceutical University1 papers (2024–2024)Nanwei Ye · Nanjing Agricultural University1 papers (2021–2021)Joshua Bauml · National Cancer Center1 papers (2024–2024)Kun Lei · Nanjing Agricultural University1 papers (2023–2023)Zhongwei Jia · King University1 papers (2024–2024)Zengpeng Lv · Nanjing Agricultural University1 papers (2021–2021)Xinlan Liu · Ningbo University1 papers (2024–2024) · 1 papers (2021–2021)Anna Minchom · Royal Marsden NHS Foundation Trust1 papers (2024–2024)Ali Alhadab · University of Minnesota, Twin Cities1 papers (2024–2024)Xiaoting Wei · Harbin Medical University1 papers (2024–2024)